🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎉 Happy birthday, HAYA! We’re celebrating 3 years of pioneering next-generation therapies for fibrotic diseases. Here’s to many more!

Amazing upcoming lab opportunity alert!📢 If you are looking for an awesome lab led by a passionate and creative unconventional scientist, who thinks out of the box, teaches improvisational theater Improv at UCSF & former drum player in a metal band, check out Michael Alexanian tweet👇

🏆 We're excited to announce that HAYA has been named TOP100 Swiss Startups' 8th Best Startup in Switzerland, and 1st in the Cardiovascular & Drug Discovery sectors! A wonderful recognition of our team's commitment to our mission!bit.ly/3DagKyK #TOP100SSU Venturelab

Check this very nice pre-print from Michael Alexanian and co-authors at Gladstone Institutes! Understanding how inflammation and fibrosis are connected it's crucial to develop better treatments for heart pathologies!

HAYA Project Scientist Heather Lynn had a great time connecting with other #fibrosis researchers this week at the Keystone Symposia in beautiful #Banff, CA, where she shared her poster on a new model to study lung fibrosis & experienced the magic of the Northern Lights. #KSFibrosis23

Our CEO & Co-Founder, Samir Ounzain (Samir Ounzain), had a great time discussing #Genomics and #precisionmedicine and the application of #machine learning and #AI to biology with Rahul Chaturvedi (Rahul Chaturvedi), Founder & CEO of Clora (Clora). Thank you @Biotech2050pod! #darkgenome

There’s still time to register for the Boston #Epigenetics Society webinar with HAYA scientific advisor John Rinn (@Noncodarnia) who will be discussing the role of #lncRNA in transcriptional regulation! TODAY at 12 p.m. ET. Register now: ow.ly/u0PG50OqJHW

Hey again, science people! To reiterate, the Cusanovich lab released 2 preprints last week! Worth repeating! Here's a 🧵on txci-ATAC-seq (biorxiv.org/content/10.110…), a method for multiplex single-cell ATAC-seq marrying combinatorial indexing and 10x microfluidic barcoding. (1/13)

Limula Biotech Lunaphore (a Bio-Techne brand) ClearSpace HUGE congratulations for the winner of Top 100 Swiss Award 2023 which is HAYA Therapeutics ! A startup based-in the canton of Vaud and at Biopôle Lausanne Innovaud is proud of them and as the CTO and Co-founder Daniel Blessing says: « The team is the key! » 🥇🏆 #top100SSU

So proud to be part of the team who made haya the number one startup in Switzerland! Very excited to see what the future hold in front of us!

Immensely proud to share our four papers on #SingleCell dissection of #Alzheimers Disease coming out in Cell today, reporting 2.3M #scRNA profiles and 850k #scATAC profiles across 427 post-mortem human brain samples from AD and non-AD donors in a wonderful

Team HAYA congratulates Sudhir Agrawal for receiving an Oligonucleotide Therapeutics Society Lifetime Achievement Award! A pioneer in antisense oligonucleotides, Professor Agrawal has been a constant supporter of our mission to deliver new generation RNA-based therapeutics targeting #lncRNA. #OTS2023

Our holiday parties hit the spot this year! Whether it was a day of aiming for targets at the World Archery Excellence Centre in Switzerland or taking aim at some good eats in California, the HAYA team enjoyed spending time together as the year comes to a close. 🥂

Clinical trial failures are often due to a lack of efficacy. I shared my thoughts with Journal of Clinical Investigation on how human data and omics analysis can translate scientific discoveries into new, more individualized medicines #MyCompany: jci.org/articles/view/…

TODAY: Don't miss HAYA's VP of Translation James Karras presenting at the #ATS2024 Respiratory Innovation Summit, during the Fibrosis Innovators Session, from 3:00 pm to 3:30 pm. For more information: lnkd.in/dbtrHH6 American Thoracic Society (ATS)

🚀 We are thrilled to announce a multi-year #collaboration with Eli Lilly and Company to discover novel #RegulatoryGenome targets for #Obesity & related #MetabolicConditions. Learn more: hayatx.com/news-and-publi…

Eli Lilly is pairing up with a so-called “dark genome” biotech startup to hunt for a new generation of obesity and metabolic drugs. endpts.com/lilly-inks-obe…

✈️ We’re just 1-week away from the #FallInternationalConvention of the #PharmaceuticalSocietyofKorea! Join us for an exciting presentation by HAYA's Dir. Biology & Funct. Genomics, rudi micheletti! Seize this opportunity to learn more about #HAYA!🧬 ➡️shorturl.at/02pBn